CoChat

Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors

Open access

Published version of a preprint

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Abstract

Purpose: To inform prognosis, treatment response, disease biology, and KRAS G12C mutation heterogeneity, we conducted exploratory circulating tumor DNA (ctDNA) profiling on 134 patients with solid tumors harboring a KRAS G12C mutation treated with single-agent divarasib (GDC-6036) in a phase 1 study. Experimental Design: Plasma samples were collected for serial ctDNA profiling at baseline (cycle 1 day 1 prior to treatment) and multiple on-treatment time points (cycle 1 day 15 and cycle 3 day 1). Results: KRAS G12C ctDNA was detectable from plasma samples in 72.9% (43/59) and 92.6% (50/54) of patients with non–small cell lung cancer and colorectal cancer, respectively, the majority of whom were eligible for study participation based on a local test detecting the KRAS G12C mutation in tumor tissue. Baseline ctDNA tumor fraction was associated with tumor type, disease burden, and metastatic sites. A decline in ctDNA level was observed as early as cycle 1 day 15. Serial assessment showed a decline in ctDNA tumor fraction associated with response and progression-free survival. Except for a few cases of KRAS G12C sub-clonality, on-treatment changes in KRAS G12C variant allele frequency mirrored changes in the overall ctDNA tumor fraction. Conclusions: Across tumor types, the KRAS G12C mutation likely represents a truncal mutation in the majority of patients. Rapid and deep decline in ctDNA tumor fraction was observed in patients responding to divarasib treatment. Early on-treatment dynamics of ctDNA were associated with patient outcomes and tumor response to divarasib treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-24-0255

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. ctDNA profiling in the phase I GO42144 study, single-agent divarasib treatment arms. A, Diagram depicting plasma sample collection time points for ctDNA profiling. B, Venn diagram showing the number of ctDNA-evaluable samples at baseline (C1D1) and early on-treatment time points (C1D15 and C3D1). C, CONSORT diagram for ctDNA profiling.
Figure 1. ctDNA profiling in the phase I GO42144 study, single-agent divarasib treatment arms. A, Diagram depicting plasma sample collection time points for ctDNA profiling. B, Venn diagram showing the number of ctDNA-evaluable samples at baseline (C1D1) and early on-treatment time points (C1D15 and C3D1). C, CONSORT diagram for ctDNA profiling.CC BY-NC-ND · PubMed Central
Figure 2. Association of baseline ctDNA tumor fraction with disease and clinical characteristics. A, Box plot showing baseline ctDNA tumor fraction by tumor type. B, Box plot showing baseline ctDNA tumor fraction by tumor type and the KRAS G12C mutation detectability in plasma samples. C, Scatter plot showing the association between ctDNA tumor fraction and tumor volume (SLD of target lesion) at baseline. D, Box plot showing baseline ctDNA tumor fraction by number of metastatic sites. E–G, Box plot showing baseline ctDNA tumor fraction by site of metastasis among patients with NSCLC (E) and colorectal cancer (F and G), respectively. H, Box plot showing baseline ctDNA tumor fraction by prior lines of systemic therapy. For the box and whisker plots in A, B, D–H, the center line represents the median, the (top) and (bottom) of the box the interquartile range, and the Ι bars 1.5 times the interquartile range.
Figure 2. Association of baseline ctDNA tumor fraction with disease and clinical characteristics. A, Box plot showing baseline ctDNA tumor fraction by tumor type. B, Box plot showing baseline ctDNA tumor fraction by tumor type and the KRAS G12C mutation detectability in plasma samples. C, Scatter plot showing the association between ctDNA tumor fraction and tumor volume (SLD of target lesion) at baseline. D, Box plot showing baseline ctDNA tumor fraction by number of metastatic sites. E–G, Box plot showing baseline ctDNA tumor fraction by site of metastasis among patients with NSCLC (E) and colorectal cancer (F and G), respectively. H, Box plot showing baseline ctDNA tumor fraction by prior lines of systemic therapy. For the box and whisker plots in A, B, D–H, the center line represents the median, the (top) and (bottom) of the box the interquartile range, and the Ι bars 1.5 times the interquartile range.CC BY-NC-ND · PubMed Central
Figure 3. Association of baseline ctDNA tumor fraction with confirmed ORR and PFS. A and B, Confirmed ORR (A) and Kaplan–Meier curves showing PFS (B) by baseline ctDNA tumor fraction in patients with NSCLC and colorectal cancer, respectively. The 95% CI is shown in the square brackets. mPFS, median PFS.
Figure 3. Association of baseline ctDNA tumor fraction with confirmed ORR and PFS. A and B, Confirmed ORR (A) and Kaplan–Meier curves showing PFS (B) by baseline ctDNA tumor fraction in patients with NSCLC and colorectal cancer, respectively. The 95% CI is shown in the square brackets. mPFS, median PFS.CC BY-NC-ND · PubMed Central
Figure 4. Association of ctDNA tumor fraction dynamics with best overall response and PFS. A and B, Shown are ctDNA tumor fraction at baseline (C1D1) and early on-treatment time points (C1D15 and C3D1) according to the best response among patients with measurable disease at baseline. Each line represents one patient. A, NSCLC: CR/PR, n = 18; SD/PD, n = 7; B, colorectal cancer: PR, n = 15; SD/PD, n = 22. C and D, Shown are changes in ctDNA tumor fraction from baseline to C1D15 or C3D1 according to the best overall response among patients with NSCLC (C) or colorectal cancer (D) with measurable disease at baseline. For the box and whisker plots in A–D, the center line represents the median, the top and bottom of the box the interquartile range, and the Ι bars 1.5 times the interquartile range. E, Forest plot showing the PFS HR (95% CI) in patients with a ctDNA reduction ≥ median vs. a ctDNA reduction < median. F and G, Kaplan–Meier curves showing PFS according to the ctDNA dynamics in patients with NSCLC (F) and colorectal cancer (G). mPFS with 95% CI in the square brackets were shown.
Figure 4. Association of ctDNA tumor fraction dynamics with best overall response and PFS. A and B, Shown are ctDNA tumor fraction at baseline (C1D1) and early on-treatment time points (C1D15 and C3D1) according to the best response among patients with measurable disease at baseline. Each line represents one patient. A, NSCLC: CR/PR, n = 18; SD/PD, n = 7; B, colorectal cancer: PR, n = 15; SD/PD, n = 22. C and D, Shown are changes in ctDNA tumor fraction from baseline to C1D15 or C3D1 according to the best overall response among patients with NSCLC (C) or colorectal cancer (D) with measurable disease at baseline. For the box and whisker plots in A–D, the center line represents the median, the top and bottom of the box the interquartile range, and the Ι bars 1.5 times the interquartile range. E, Forest plot showing the PFS HR (95% CI) in patients with a ctDNA reduction ≥ median vs. a ctDNA reduction < median. F and G, Kaplan–Meier curves showing PFS according to the ctDNA dynamics in patients with NSCLC (F) and colorectal cancer (G). mPFS with 95% CI in the square brackets were shown.CC BY-NC-ND · PubMed Central
Figure 5. Rare cases of KRAS G12C mutation heterogeneity. A and B, Scatter plot showing the association between the change in ctDNA tumor fraction and changes in KRAS G12C VAF from baseline (C1D1) to C1D15 (A) or C3D1 (B). C–E, Shown are three cases where the KRAS G12C mutation was identified to be subclonal. Spaghetti plot showing the VAF of specific RAS/RAF oncogenic driver mutations, TP53 alterations, and overall ctDNA tumor fraction as assessed by longitudinal ctDNA profiling.
Figure 5. Rare cases of KRAS G12C mutation heterogeneity. A and B, Scatter plot showing the association between the change in ctDNA tumor fraction and changes in KRAS G12C VAF from baseline (C1D1) to C1D15 (A) or C3D1 (B). C–E, Shown are three cases where the KRAS G12C mutation was identified to be subclonal. Spaghetti plot showing the VAF of specific RAS/RAF oncogenic driver mutations, TP53 alterations, and overall ctDNA tumor fraction as assessed by longitudinal ctDNA profiling.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 34 references

Cited by

See all 23

Metadata

Authors
Choi, Y., Dharia, N. V., Jun, T., Chang, J., Royer-Joo, S., Yau, K. K., Assaf, Z. J., Aimi, J., Sivakumar, S., Montesion, M., Sacher, A., LoRusso, P., Desai, J., Schutzman, J. L., Shi, Z., & and the GO42144 study group
Affiliations
  • Genentech (US)
  • Genentech, Inc., South San Francisco, California. 1
  • Roche (Canada) (CA)
  • Foundation Medicine (United States) (US)
  • University Health Network (CA)
  • Yale Cancer Center (US)
  • The University of Melbourne (AU)
Corresponding author
Shi, Zhen
Venue
Clinical Cancer Research
Published
2024-07-12
Volume
30
Issue
17
Pages
3788-3797
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W4400582488
Cited by
23
References
34
Citations by year
2026: 10 · 2025: 10 · 2024: 3
FWCI
4.61
Type
journal article
Language
en
Open access
Locations
  • Clinical Cancer Research (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-nd)
Funders
  • National Institutes of Health (UL1TR001863)
  • National Center for Advancing Translational Sciences
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Keywords
circulating tumor DNA, KRAS G12C mutation, divarasib, KRAS G12C inhibitors, treatment response monitoring, variant allele frequency, non-small cell lung cancer, colorectal cancer, solid tumors, liquid biopsy
MeSH terms
Circulating Tumor DNA, Adult, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung, Female, Humans, Male, Middle Aged, Mutation, Neoplasms, Prognosis, Biomarkers, Tumor, Proto-Oncogene Proteins p21(ras), Treatment Outcome, Genetic Heterogeneity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-24-0255
The paper
Choi, Y., Dharia, N. V., Jun, T., Chang, J., Royer-Joo, S., Yau, K. K., Assaf, Z. J., Aimi, J., Sivakumar, S., Montesion, M., Sacher, A., LoRusso, P., Desai, J., Schutzman, J. L., Shi, Z., & and the GO42144 study group. (2024). Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-24-0255

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.